MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Short Interest Down 76.0% in June

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) was the recipient of a large decrease in short interest in the month of June. As of June 30th, there was short interest totalling 15,600 shares, a decrease of 76.0% from the June 15th total of 64,900 shares. Approximately 0.2% of the shares of the stock are sold short. Based on an average trading volume of 111,400 shares, the days-to-cover ratio is presently 0.1 days.

Institutional Investors Weigh In On MIRA Pharmaceuticals

Hedge funds have recently modified their holdings of the company. Praetorian Wealth Management Inc. bought a new position in shares of MIRA Pharmaceuticals during the first quarter valued at $30,000. Suncoast Equity Management acquired a new stake in MIRA Pharmaceuticals during the 1st quarter valued at approximately $44,000. Virtu Financial LLC raised its holdings in MIRA Pharmaceuticals by 330.2% during the 1st quarter. Virtu Financial LLC now owns 63,055 shares of the company’s stock worth $69,000 after purchasing an additional 48,397 shares during the last quarter. Finally, Cross Staff Investments Inc bought a new stake in shares of MIRA Pharmaceuticals in the 1st quarter valued at $422,000. Institutional investors and hedge funds own 35.16% of the company’s stock.

MIRA Pharmaceuticals Price Performance

MIRA traded up $0.04 on Thursday, hitting $0.60. 20,331 shares of the stock were exchanged, compared to its average volume of 390,540. MIRA Pharmaceuticals has a 12 month low of $0.51 and a 12 month high of $7.98. The business has a 50-day moving average of $0.73 and a two-hundred day moving average of $0.93. The firm has a market capitalization of $8.87 million and a price-to-earnings ratio of -0.90.

MIRA Pharmaceuticals (NASDAQ:MIRA) last posted its earnings results on Monday, May 13th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). Equities research analysts expect that MIRA Pharmaceuticals will post -0.62 earnings per share for the current fiscal year.

MIRA Pharmaceuticals Company Profile

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.